.... A total of 65,775 sICH-free controls were randomly selected at a ratio of 1:15 from individuals with the same birth year and sex according to a nested case-control study design. Results: Although the incidence rate of sICHs started to decrease from 2007 onward, the use of antiplatelets, anticoagulants...

... were not on any antiplatelet treatment. The prevalence of severe stroke was lower in patients who were receiving clopidogrel than in patients who were receiving aspirin and patients who were not on antiplatelets (1.4, 13.0 and 11.0%, respectively; p < 0.05). Independent predictors of severe stroke...

...Christian Weimar; Dan Cotton; Nanshi Sha; Ralph L. Sacco; Philip M.W. Bath; Ralph Weber; Hans Christoph Diener; for the PRoFESS study group Background: Several case control studies have reported an increased risk of cardiovascular events following discontinuation of antiplatelet agents in high-risk...

...%) overall received antiplatelet agents, and 12 (2.4%) received oral anticoagulation. No difference could be found for recurrent ICH under antiplatelet agents versus no antithrombotic medication. Conclusion: The risk of recurrent stroke after lobar ICH remains high beyond the first year, whereas it decreases...

... effective than placebo or heparin, even in NVAF, but other antiplatelet agents have not been evaluated. 3 4 2009 © 2009 S. Karger AG, Basel 2009 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced...

... and the frequencies of stroke subtypes tend to converge throughout the world. However, the ratio of stroke to ischemic heart disease is still different between the East and West. Comparison of various countries’ guidelines shows that recommendations on antiplatelet therapy for secondary prevention of ischemic stroke...

... of neutropenia, affecting less than 1 % of patients, makes the benefit-risk ratio a reasonable one. Meta-analysis of pooled antiplatelet stroke prevention trials and antiplatelet studies in other indications add statistical strength to these observations and yield important new inferences in subgroups of risk...